| Lupus Nephritis |
2005-003070-19: A randomized, multicenter, parallel-group, open-label study to assess the efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic®) versus continuation of previous therapy in patients with proliferative lupus nephritis on standard maintenance therapy |
|
|
| Ongoing | 2 | 16 | Europe | Myfortic, ERL080A, Myfortic, Myfortic | Novartis Pharma Services AG | lupus nephritis ( as part of the disease \"Systemic Lupus Erythematosus\") | | | | |
| Completed | 2 | 126 | Europe, US, RoW | Mycophenolate Mofetil/Mycophenolic Acid, Obinutuzumab, Gazyva, GA101, RO5072759, Placebo, Methylprednisolone, Prednisone | Hoffmann-La Roche | Lupus Nephritis | 01/19 | 08/23 | | |
|
|
|
|
NCT03453619: Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies |
|
|
| Completed | 2 | 21 | US | APL-2 | Apellis Pharmaceuticals, Inc. | IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis, Dense Deposit Disease | 04/20 | 08/23 | | |
2020-001537-13: Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) |
|
|
| Not yet recruiting | 2 | 120 | Europe | Ravulizumab, ALXN1210, Concentrate for solution for infusion, Ultomiris | Alexion Pharmaceuticals, Inc., ALEXION PHARMACEUTICALS INCORPORATED, Alexion Pharmaceuticals, Inc. | Lupus Nephritis (LN)Immunoglobulin A Nephropathy (IgAN), Lupus Nephritis (LN)Immunoglobulin A Nephropathy (IgAN), Diseases [C] - Immune System Diseases [C20] | | | | |
2021-000097-29: A Phase II Randomized Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescent Patients with Active Class III or IV Lupus Nephritis Estudio fase II, aleatorizado y controlado paraevaluar la eficacia, seguridad y farmacocinética de obinutuzumab en pacientes adolescentes con nefritis lúpica de casle III o IV activa |
|
|
| Not yet recruiting | 2 | 30 | Europe | Obinutuzumab, mycophenolate mofetil, RO5072759, Concentrate for solution for infusion, Tablet, Gazyvaro, Myfenax | Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F. Hoffman-La Roche Ltd., F. HOFFMANN - LA ROCHE LTD., F. Hoffman-La Roche Ltd. | Lupus Nephritis (LN) Nefritis lúpica (NL), Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE). SLE is an autoimmune disease, in which the body’s immune system attacks its own healthy body tissue. La nefritis lúpica es una inflamación del riñón causada por el lupus eritematoso sistémico(LES).LES es una enfermedad autoinmune,en la que el sistema inmune del cuerpo ataca sus propios tejidos sanos, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT04835883: Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients |
|
|
| Recruiting | 2 | 10 | RoW | CS20AT04 (allogenic bone marrow derived mesenchymal stem cell) | Hanyang University Seoul Hospital, Corestem, Inc., Ministry of Health & Welfare, Korea | Systemic Lupus Erythematosus | 11/21 | 01/26 | | |
2020-005568-79: A Clinical Study of Nipocalimab in Adult Participants with Active Lupus Nephritis |
|
|
| Not yet recruiting | 2 | 80 | Europe | Nipocalimab, JNJ-80202135, Solution for infusion | Janssen-Cilag International NV, Janssen Research & Development, LLC | Active Lupus Nephritis, Lupus Nephritis, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT04924296: A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis |
|
|
| Not yet recruiting | 2 | 60 | NA | SHR-1314, Placebo | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Lupus Nephritis | 12/21 | 09/22 | | |
| Terminated | 2 | 31 | Europe, Canada, RoW | Placebo, Cemdisiran, ALN-CC5 | Alnylam Pharmaceuticals | IgA Nephropathy (IgAN), Berger Disease, Glomerulonephritis, IgA | 03/22 | 06/23 | | |
2022-000243-80: LUPUS NEPHRITIS TREATMENT WITH MESENCHYMAL CELLS (MSV-allo®). TRATAMIENTO DE LA NEFRITIS LÚPICA con células mesenquimales (MSV-allo®). |
|
|
| Ongoing | 2 | 20 | Europe | Allogeneic adult mesenchymal stem cells bone marrow derived expanded in suspension, MSV®-allo, Suspension for injection | Hospital Universitario Rio Hortega, En tramite | Lupus nephritis Nefritis lúpica, Lupus nephritis Nefritis lúpica, Diseases [C] - Immune System Diseases [C20] | | | | |
2021-002046-33: Study of efficacy and safety of LNP023 in participants with active lupus nephritis Class III-IV, +/- V Az LNP023 hatásosságának és biztonságosságának vizsgálata III-IV-es, +/- V-ös osztályú, aktív lupus nephritisben szenvedő résztvevők körében |
|
|
| Ongoing | 2 | 240 | Europe | Iptacopan, Prednisone, LNP023, Capsule, hard, Capsule, hard + tablet, Prednisone | Novartis Pharma AG, Novartis Farmacéutica S.A., Novartis Pharma AG | Lupus Nephritis Class III-IV, +/- V, Autoimmune disease, Diseases [C] - Immune System Diseases [C20] | | | | |
| Active, not recruiting | 2 | 13 | Europe, US, RoW | Pegcetacoplan | Apellis Pharmaceuticals, Inc. | C3G, IC-MPGN, Renal Transplant, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Dense Deposit Disease (DDD), Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulonephritis | 02/23 | 01/26 | | |
2018-003155-38: A Study of the Efficacy and Safety of Guselkumab in Participants with Active Lupus Nephritis |
|
|
| Not yet recruiting | 2 | 60 | Europe | Guselkumab, CNTO1959, Solution for injection in pre-filled syringe, TREMFYA | Janssen-Cilag International NV, Janssen Research & Development | Active Lupus Nephritis, Active Lupus Nephritis, Diseases [C] - Immune System Diseases [C20] | | | | |
| Terminated | 2 | 33 | Europe, US, RoW | Guselkumab Dose 1, CNTO 1959, Placebo, Guselkumab Dose 2, CNTO1959, Standard-of-care treatment | Janssen Research & Development, LLC | Lupus Nephritis | 02/23 | 02/23 | | |
ChiCTR2400081359: Clinical outcomes of abatacept in patients with refractory lupus nephritis: Phase II study |
|
|
| Completed | 2 | 17 | | Abatacept 125mg/week subcutaneously | Renji Hospital, Shanghai Jiao Tong University School of Medicine; Renji Hospital, Shanghai Jiao Tong University School of Medicine, Self-financed by the researcher | lupus nephritis | | | | |
| Completed | 2 | 57 | Europe, RoW | CFZ533, Placebo | Novartis Pharmaceuticals | Lupus Nephritis | 06/23 | 06/23 | | |
|
NCT05714670: The Effect of Curcumin on the Clinical Outcome of Pediatric Patients With Active Lupus Nephritis |
|
|
| Recruiting | 2 | 72 | RoW | Curcumin Oral Capsule, Turmeric | Ain Shams University | Lupus Nephritis, SLE Nephritis | 10/23 | 08/24 | | |
NCT06155604: SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease |
|
|
| Not yet recruiting | 2 | 150 | RoW | Dapagliflozin 10mg Tab, Farxiga, Forxiga, Standard maintenance therapy, Cellcept, Imuran | The University of Hong Kong | Lupus Nephritis, Chronic Kidney Diseases | 11/26 | 11/26 | | |
PRUNE, NCT05101447: Pharmacokinetically-driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis |
|
|
| Withdrawn | 2 | 58 | NA | Mycophenolate Mofetil | Children's Hospital Medical Center, Cincinnati | Lupus Nephritis | 01/24 | 07/24 | | |
| Recruiting | 2 | 70 | Europe, US, RoW | ALXN2050, ACH-0145228 (formerly), Placebo | Alexion Pharmaceuticals, Inc. | Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN | 06/26 | 06/26 | | |
| Completed | 2 | 24 | Europe, RoW | MOR202 | HI-Bio | Glomerulonephritis, Membranous Nephropathy, antiPLA2R Positive | 12/23 | 12/23 | | |
| Completed | 2 | 177 | RoW | Zanubrutinib, BGB-3111, Brukinsa, Placebo | BeiGene | Lupus Nephritis | 02/24 | 08/24 | | |
NCT06209736: Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN |
|
|
| Recruiting | 2 | 20 | Europe, RoW | OMS906 study drug, OMS906 | Omeros Corporation | C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis | 01/25 | 04/26 | | |
SANCTUARY, NCT04564339: Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) |
|
|
| Recruiting | 2 | 120 | Europe, Canada, US, RoW | Ravulizumab, Ultomiris, Placebo, Background Therapy | Alexion Pharmaceuticals, Inc. | Lupus Nephritis, Immunoglobulin A Nephropathy | 04/25 | 05/26 | | |
| Recruiting | 2 | 12 | US | Daratumumab | Mayo Clinic | Lupus Nephritis | 07/26 | 07/26 | | |
ADX-097-201, NCT06419205: A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G |
|
|
| Not yet recruiting | 2 | 30 | NA | ADX-097 | Q32 Bio Inc. | IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy | 12/25 | 12/25 | | |
NCT06295770: Obinutuzumab in Treatment of Fibrillary Glomerulonephritis |
|
|
| Recruiting | 2 | 20 | US | Obinutuzumab, Gazyva | Mayo Clinic | Fibrillary Glomerulonephritis | 05/26 | 05/26 | | |
| Recruiting | 2 | 20 | Europe | Mesenchymal stem cells (MSC), MSV, GMP-compliant MSC manufactured by IBGM in Valladolid, Placebo, Saline solution | Red de Terapia Celular, Hospital del Río Hortega, Hospital Clínico Universitario de Valladolid, University of Valladolid, Citospin | Lupus Nephritis, Lupus Erythematosus | 07/25 | 07/26 | | |
NCT05810948: A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013) |
|
|
| Recruiting | 2 | 60 | RoW | efgartigimod IV, Placebo | argenx, Zai Lab (Shanghai) Co., Ltd. | Lupus Nephritis | 08/24 | 10/24 | | |
RESULT, NCT06500702: A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease |
|
|
| Not yet recruiting | 2 | 84 | NA | frexalimab, SAR442970, rilzabrutinib, placebo | Sanofi | Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion | 12/26 | 02/28 | | |
NCT06581198: A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN) |
|
|
| Recruiting | 2 | 144 | US, RoW | rapcabtagene autoleucel Regimen 1, rapcabtagene autoleucel Regimen 2, Standard of Care | Novartis Pharmaceuticals | Lupus Erythematosus, Systemic, Lupus Nephritis | 05/29 | 05/30 | | |
| Recruiting | 2 | 240 | Europe, US, RoW | Iptacopan (part 1), LNP023, Iptacopan (part 2), Placebo + standard of care, Iptacopan + placebo, LNP023 and placebo | Novartis Pharmaceuticals, Novartis Pharma AG | Lupus Nephritis | 10/24 | 03/28 | | |
NCT00977977: Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy |
|
|
| Recruiting | 2 | 30 | US | Rituximab Infusion, Oral Cyclosporine | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Nephrotic Syndrome, Proteinuria, Autoimmune Disease, Glomerular Disease, Membranous Glomerulonephritis | 12/24 | 01/25 | | |
| Recruiting | 2 | 39 | RoW | MSC treatment, Cellistem ® Lupus, Standard of Care, Standard of Care for Lupus Nephritis, Placebo, Placebo (for MSC) | Universidad de los Andes, Chile | Lupus Erythematosus, Systemic, Lupus Glomerulonephritis | 12/24 | 12/25 | | |
| Recruiting | 2 | 30 | Europe | Aliskiren, Enalapril | Region Skane | C3 Glomerulopathy, Membranoproliferative Glomerulonephritis, Complement Abnormality, Dense Deposit Disease, C3 Glomerulonephritis | 12/29 | 12/29 | | |
| Recruiting | 2 | 120 | RoW | Telitacicept 240 mg, RC18 240 mg, Telitacicept 160 mg, RC18 160 mg, Placebo | RemeGen Co., Ltd. | Lupus Nephritis | 12/25 | 01/26 | | |
SPARTAN, NCT04663204: A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy |
|
|
| Active, not recruiting | 2 | 12 | Europe | Sparsentan, RE-021 | University of Leicester, Travere Therapeutics, Inc. | Immunoglobulin A Nephropathy, Kidney Diseases, Glomerulonephritis, IGA, Glomerulonephritis, Autoimmune Diseases, Immune System Diseases | 03/25 | 03/25 | | |
| Recruiting | 2 | 105 | US | Mycophenolate Mofetil, MMF dosed per body surface area, MMF dosed phrmacokinetically | Children's Hospital Medical Center, Cincinnati, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Genentech, Inc. | Lupus Nephritis | 07/25 | 03/26 | | |
NCT05654506: Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits |
|
|
| Recruiting | 2 | 40 | US | Daratumumab | Mayo Clinic | Proliferative Glomerulonephritis With Monoclonal IgG Deposits | 08/26 | 08/26 | | |
| Terminated | 2 | 19 | Europe, US, RoW | Daxdilimab, Placebo (Normal Saline) | Amgen, Horizon Therapeutics Ireland DAC | Lupus Nephritis | 01/24 | 01/24 | | |
NCT05517980: Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis |
|
|
| Not yet recruiting | 2 | 52 | NA | KP104 | Kira Pharmacenticals (US), LLC. | Glomerulonephritis | 09/25 | 09/25 | | |
| Recruiting | 2 | 80 | Europe, RoW | ALE.F02, Rituximab, GlucoCorticoid, Cyclophosphamid, Placebo, Immunosuppressive Agents | Alentis Therapeutics AG | Glomerulonephritis Rapidly Progressive | 09/25 | 09/25 | | |
NCT06058078: RY_SW01 Cell Injection Therapy in Active Lupus Nephritis |
|
|
| Recruiting | 2 | 60 | RoW | RY_SW01 cell injection, UC-MSC treatment, Basic treatment, Immunosuppressive drugs | Jiangsu Renocell Biotech Company, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Lupus Nephritis | 12/25 | 12/28 | | |
POSTERITY, NCT05039619 / 2021-000097-29: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants |
|
|
| Recruiting | 2 | 40 | Europe, Canada, US, RoW | Obinutuzumab, Gazyva, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone | Hoffmann-La Roche, Genentech, Inc. | Lupus Nephritis | 03/26 | 03/29 | | |
| Recruiting | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
ChiCTR2400083898: Population pharmacokinetic study of Telitacicept in children with lupus nephritis |
|
|
| Not yet recruiting | 2 | 50 | | During the screening period, eligible subjects who met the inclusion criteria were administered the study drug at baseline (Day 0), 7, 14, 21, 28 days, and then weekly for a total treatment duration of 24 weeks. | Children’s Hospital of Fudan University; Children’s Hospital of Fudan University, Transverse research project of Children’s Hospital of Fudan University | pediatric lupus nephritis | | | | |
| Recruiting | 2 | 74 | US | VIB4920, Placebo for VIB4920 | National Institute of Allergy and Infectious Diseases (NIAID) | Lupus Nephritis | 08/26 | 03/27 | | |
| Not yet recruiting | 2 | 80 | US | Placebo, Nipocalimab, JNJ-80202135, M281, Standard-of-care treatment | Janssen Research & Development, LLC, Janssen Research & Development, LLC | Lupus Nephritis | 02/28 | 02/28 | | |
| Recruiting | 1/2 | 2000 | US | PurWet, FurFat, PurApo, PurPhl, PurClo, PurInf, Smoliv | All Natural Medicine Clinic, LLC | Sequelae of; Infection, Post Infection Glomerulonephritis, Post-Infectious Peripheral Neuralgia, Post-Infectious Disorder (Disorder), Post-Infectious Arthritis, Post-Infectious Polyneuritis, Post-Infectious Parkinsonism, Post-Infectious Hypothyroidism, Post Infectious Osteoarthritis, Anxiety Disorders, Depression, Depression, Anxiety, Depression, Bipolar, Insomnia, GERD, Gastro Esophageal Reflux, Hepatitis, Glomerulonephritis | 05/22 | 10/22 | | |
KYSA-3, NCT06342960: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis |
|
|
| Recruiting | 1/2 | 32 | Europe | KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen, Cyclophosphamide, Fludarabine | Kyverna Therapeutics | Lupus Nephritis, Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV | 10/28 | 01/29 | | |
2022-001796-14: An open-label study to assess safety, efficacy and cellular kinetics of YTB323 in severe, refractory systemic lupus erythematosus (srSLE). |
|
|
| Not yet recruiting | 1/2 | 12 | Europe | YTB323, Dispersion for infusion | Novartis Pharma AG, Novartis Farmacéutica, S.A., Novartis Pharma AG | Systemic Lupus ErythematosusLupus Nephritis, Systemic Lupus ErythematosusLupus Nephritis, Diseases [C] - Immune System Diseases [C20] | | | | |
NCT06153095: A Study of IMPT-514 in Active Refractory Systemic Lupus Erythematosus (SLE) |
|
|
| Recruiting | 1/2 | 30 | US, RoW | IMPT-514 | ImmPACT Bio | Systemic Lupus Erythematosus, Lupus Nephritis | 02/27 | 02/27 | | |
NCT06585514: Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus |
|
|
| Not yet recruiting | 1/2 | 18 | NA | | Beijing GoBroad Hospital | Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN) | 09/25 | 12/25 | | |
BAH242, NCT06350110: Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) |
|
|
| Not yet recruiting | 1/2 | 75 | RoW | CD19- BCMA CAR-T cells, EB-BH2024-2 | Essen Biotech | Systemic Lupus Erythematosus, Lupus Nephritis, Autoimmune Diseases, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis, Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Sjogren's Syndrome | 12/25 | 12/25 | | |
NCT06113900: Assessment of Safety and Efficacy of SGLT2is Among LN Patients |
|
|
| Not yet recruiting | 1/2 | 50 | RoW | Dapagliflozin 10mg Tab orally once daily, Empagliflozin 10 mg tab orally once daily | Ain Shams University | Lupus Nephritis | 12/24 | 01/25 | | |
NCT05938725: KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis |
|
|
| Recruiting | 1/2 | 32 | US | KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen, Cyclophosphamide, Fludarabine | Kyverna Therapeutics | Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV | 08/25 | 08/26 | | |
| Recruiting | 1/2 | 56 | US, RoW | povetacicept, ALPN-303 | Alpine Immune Sciences, Inc. | Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 01/26 | 01/26 | | |
NCT05798117: An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1/2 | 24 | Europe, US, RoW | YTB323 | Novartis Pharmaceuticals | Systemic Lupus Erythematosus, Lupus Nephritis | 10/26 | 10/26 | | |
ChiCTR2400081474: A clinical study of Telitacicept combined with traditional regimens in refractory lupus nephritis in children |
|
|
| Recruiting | 1/2 | 34 | | Telitacicept+ Standard treatment | Children's Hospital of Fudan University; Children's Hospital of Fudan University, Self-funded | Lupus nephritis | | | | |
RESET-SLE, NCT06121297: a Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Systemic Lupus Erythematosus |
|
|
| Recruiting | 1/2 | 12 | US | CABA-201 | Cabaletta Bio | Systemic Lupus Erythematosus, Lupus Nephritis | 12/27 | 12/27 | | |
